Contractor
AN2 THERAPEUTICS, INC
MENLO PARK, CA
- UEI
- DD4FE2GE4L78
- Parent UEI
- DD4FE2GE4L78
- Resolved by
- uei
- Confidence
- 1.000
Obligated to date
$9,235,5771
Awards
1
Agencies served
1
Active from Sep 20, 2022 to Aug 18, 2026.
Sign in to watchRecent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 75N93022C00059 DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS. | Department of Health and Human Services | CA | Sep 20, 2022 | $9,235,577 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier DD4FE2GE4L78, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Sep 12, 2026.